Asset Details
Do you wish to reserve the book?
Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine
Do you wish to request the book?
Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine
2026
Overview
Haemophilus influenzae type a (Hia) disease is associated with fatality and morbidity, predominantly in children from Northern indigenous communities in Canada and Alaska. Symptoms include but are not limited to meningitis, sepsis, pneumonia, otitis media and bacteremia. A key virulence factor associated with Hia pathogenesis is the bacterial capsular polysaccharides. Prophylactic vaccines targeting the capsular polysaccharide (CPS) antigens is considered a promising intervention strategy given the effectiveness of polysaccharide-protein conjugate vaccines against diverse bacterial pathogens. In the same vein, we in this study have presented the development of Hia conjugate vaccine involving hydrazide-polyethylene glycol-hydrazide linker with rCRM197 as a carrier protein. Preclinical immunogenicity data indicated induction of robust serum bactericidal antibody responses at a 10-μg CPS antigen dose in rabbits like the PedvaxHIB® comparator, leading to evaluation of the Hia vaccine candidate in Phase I clinical trials.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Age
/ Alaska
/ Animals
/ Antibodies, Bacterial - blood
/ Antigens
/ Canada
/ death
/ Female
/ Glycoconjugates - immunology
/ Haemophilus Infections - immunology
/ Haemophilus Infections - prevention & control
/ Haemophilus influenzae - immunology
/ Haemophilus Vaccines - administration & dosage
/ Haemophilus Vaccines - immunology
/ Hia
/ Humans
/ Hydrazide-polyethylene glycol-hydrazide linker
/ otitis
/ Polysaccharides, Bacterial - immunology
/ Proteins
/ Rabbits
/ rCRM197
/ Sepsis
/ Vaccines
/ Vaccines, Conjugate - administration & dosage
